1. Home
  2. ALT
  3. Earnings

AI Earnings Predictions for Altimmune Inc. (ALT)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

BUY

1-Day Prediction

+3.93%

$1.69

74% positive prob.

5-Day Prediction

+5.71%

$1.72

74% positive prob.

20-Day Prediction

+6.62%

$1.73

70% positive prob.

Price at prediction: $1.63 Confidence: 47.4% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 BUY +3.93% +5.71% +6.62% 47.4% Pending
Q2 2026 BUY +6.35% +7.91% +8.51% 99.9% Pending
Q1 2026 SELL +0.75% -10.79% -6.83% 100.0% -6.62%
Q4 2025 BUY +7.25% +8.80% +10.73% 99.9% Pending
Q3 2025 BUY +7.84% +9.95% +6.28% 100.0% +3.05%

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K BUY

Nov 12, 2026 · 47% conf.

AI Prediction BUY

1D

+3.93%

$1.69

Act: +1.54%

5D

+5.71%

$1.72

20D

+6.62%

$1.73

Price: $1.63 Prob +5D: 74% AUC: 1.000
0001326190-26-000067

EX-99.1

2 alt-ex99d1.htm

EX-99.1

Exhibit 99.1

Altimmune Announces Third Quarter 2026 Financial Results and Business Update

​

Global PERFORMA Phase 3 trial in MASH progressing as planned

Positive RECLAIM Phase 2 data in AUD highlighted in a late-breaking oral presentation

at AASLD The Liver Meeting® 2026

End-of-Phase 2 meeting with FDA for AUD program scheduled for December 2026

$480 million in cash, cash equivalents and investments as of September 30, 2026

Webcast to be held today at 8:30 a.m. ET

​

MORRISTOWN, NJ – November 12, 2026 – Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 dual receptor agonist, in serious liver diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a corporate update.

“We continue to make significant progress across all our clinical development programs, as we execute our strategy of building a liver franchise around pemvidutide” said Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune. “Our global PERFORMA Phase 3 trial in MASH is ramping up, and we are very encouraged by the progress to date and the enthusiasm we see from the MASH community. In AUD, we look forward to engaging with the FDA in an End-of-Phase 2 meeting where we will leverage our strong RECLAIM data to discuss a Phase 3 registrational program. Following the recent AASLD meeting, our conviction in pemvidutide’s potential is stronger than ever, as we focus on delivering meaningful benefit to patients with serious liver diseases.”

​

Key Highlights and Anticipated Milestones

​

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

●Pemvidutide was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) based on 24-week data from the IMPACT Phase 2b trial

●IMPACT Phase 2b 48-week data published in The Lancet Gastroenterology & Hepatology in a paper titled “Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study”

●The global PERFORMA Phase 3 MASH trial is progressing as planned

●The PERFORMA 52-week topline data readout is anticipated in 2029

​

Alcohol Use Disorder (AUD)

●Pemvidutide was granted Fast Track designation by the FDA for the treatment of AUD

●An End-of-Phase 2 meeting with the FDA is scheduled for December 2026 to discuss the Phase 3 registrational program in AUD

​

Alcohol-associated Liver Disease (ALD)

●Enrollment is complete in the RESTORE Phase 2 trial in ALD, with topline data expected in the second half of 2027

​

Scientific Data on Pemvidutide in MASH and AUD Presented at AASLD The Liver Meeting® 2026

●A late-breaking oral presentation: Efficacy and Safety of Pemvidutide in the Treatment of Adults with Alcohol Use Disorder: Results from RECLAIM, a 24-Week Phase 2 Randomized Double-Blind Placebo Controlled Trial on the RECLAIM Phase 2 data in AUD was delivered by Dr. Henry R. Kranzler, University of Pennsylvania Perelman School of Medicine

●An oral presentation: Pemvidutide Treatment Results in Concurrent Reductions in Multiple Non-Invasive Tests for Hepatic Inflammation and Fibrosis: 48-Week Responder Analyses of the IMPACT Phase 2b Trial in Metabolic Dysfunction-Associated Steatohepatitis was delivered by Dr. Naim Alkhouri, Summit Clinical Research

●A poster presentation: Gastrointestinal Tolerability of Pemvidutide Without Dose Titration in Patients with Metabolic Dysfunction-Associated Steatohepatitis from the Phase 2b IMPACT Trial

●An oral presentation: Pemvidutide Treatment Reduces Alcohol Intake in a Lean Golden Syrian Hamster Model

​

Corporate Updates

●In October 2026, the Company appointed Peter Greenleaf and Alex Howarth to the Board of Directors to support its strategic evolution

●In November 2026, the Company relocated its corporate headquarters to Morristown, New Jersey

​

Financial Results for the Three Months Ended September 30, 2026

●Altimmune reported cash, cash equivalents and investments totaling $480 million as of September 30, 2026

●Research and development (R&D) expenses were $27.0 million for the three months ended September 30, 2026, compared to $15.0 million in the same period in 2025, with the increase driven primarily by the ongoing PERFORMA Phase 3 trial in MASH and RESTORE Phase 2 trial in ALD. R&D expenses for the quarter ended September 30, 2026, included $20.3 million in direct costs related to pemvidutide development activities

●General and administrative (G&A) expenses were $8.7 million for the three months ended September 30, 2026, compared to $5.9 million in the same period in 2025. The increase was driven primarily by an increase in compensation expenses and professional services

●Interest income was $4.8 million for the three months ended September 30, 2026

●Net loss for the three months ended Septembe

2026
Q2

Q2 2026 Earnings

8-K BUY

Aug 12, 2026 · 100% conf.

AI Prediction BUY

1D

+6.35%

$3.12

Act: -1.71%

5D

+7.91%

$3.16

20D

+8.51%

$3.18

Price: $2.93 Prob +5D: 100% AUC: 1.000
0001326190-26-000049

EX-99.1

2 alt-20260812xex99d1.htm

EX-99.1

Exhibit 99.1

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

​

Initiated global PERFORMA Phase 3 trial in MASH

Reported positive topline data from RECLAIM Phase 2 trial in AUD

Completed patient enrollment in RESTORE Phase 2 trial in ALD

$519 million in cash, cash equivalents and investments as of June 30, 2026

Webcast to be held today at 8:30 a.m. ET

​

GAITHERSBURG, MD – August 12, 2026 – Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.

“We have achieved several important milestones as we continue to successfully execute our strategy, including the initiation of the PERFORMA Phase 3 MASH trial and positive topline data from the RECLAIM Phase 2 AUD trial. The team remains focused on advancing our differentiated pemvidutide franchise in both MASH and AUD, each an area of unmet need with substantial future sales potential,” said Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune. “We are also pleased to announce completion of enrollment in the RESTORE Phase 2 ALD trial. Our momentum positions Altimmune to deliver on our goals of bringing pemvidutide to patients with serious liver diseases and creating value for shareholders.”

​

Key Highlights and Anticipated Milestones

​

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

●Pemvidutide was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) based on 24-week data from the IMPACT Phase 2b trial

●In August 2026, the Company announced the initiation of the global PERFORMA Phase 3 MASH trial, with 52-week data readout anticipated in 2029

oThe PERFORMA trial is a Phase 3, Global, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects with MASH

​

Alcohol Use Disorder (AUD)

●In July 2026, the Company reported positive topline results from the RECLAIM Phase 2 trial of pemvidutide in AUD

oThe RECLAIM trial evaluated the safety and efficacy of pemvidutide versus placebo in 100 patients with AUD over a 24-week treatment period

oPemvidutide achieved a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial

oImportant secondary endpoints were also met, including a 2-level reduction in WHO-risk drinking levels and zero heavy drinking days, both recognized by the FDA as registrational endpoints

oA generally favorable safety and tolerability profile was observed in the trial

oThe Company plans to request an End-of-Phase 2 meeting with the FDA and engage with the European regulatory agencies to discuss a path forward in AUD

oThe FDA granted Fast Track designation to pemvidutide for the treatment of AUD

​

Alcohol-associated Liver Disease (ALD)

●In July 2026, the Company completed patient enrollment in the RESTORE Phase 2 trial of pemvidutide in ALD

oThe RESTORE trial is a 48-week study evaluating the safety and efficacy of pemvidutide versus placebo in approximately 120 patients with liver disease due to excessive alcohol consumption

oThe trial enrolled patients with ALD and a history of chronic and heavy drinking at baseline

oTo support future regulatory discussions, the Company has amended the trial protocol to more fully evaluate the liver benefits pemvidutide may provide after one year of treatment in the ALD population

oThe primary endpoint, change from baseline in Liver Stiffness Measurement (LSM), will now be assessed hierarchically at Week 48 and then at Week 24

oThe secondary endpoints include changes in Enhanced Liver Fibrosis (ELF) score, alcohol consumption and body weight

oThe Company expects to report topline data in the second half of 2027

​

Corporate Updates

●In April 2026, the Company completed an oversubscribed public offering of common stock, pre-funded warrants, and stock warrants, resulting in gross proceeds of $225.0 million

●In June 2026, the Company announced plans to relocate its corporate headquarters to Morristown, New Jersey later in 2026

​

​

​

​

Financial Results for the Three Months Ended June 30, 2026

●Altimmune reported cash, cash equivalents and investments totaling $519 million as of June 30, 2026

●Research and development (R&D) expenses were $18.7 million for the three months ended June 30, 2026, compared to $17.2 million in the same period in 2025, with the increase driven primarily by the ongoing ALD trial as well as the startup costs for the PERFORMA Phase 3 trial in MASH, partially offset by the decrease in expenses related to completion of the IMPACT Phase 2b trial in MASH, which was ongoing in 2025. R&D expenses for the quarter ended June 30, 2026, included $11.6 million in direct costs related to pemvidutid

2026
Q1

Q1 2026 Earnings

8-K SELL

May 13, 2026 · 100% conf.

AI Prediction SELL

1D

+0.75%

$3.04

Act: -3.31%

5D

-10.79%

$2.69

Act: -6.62%

20D

-6.83%

$2.81

Act: -14.24%

Price: $3.02 Prob +5D: 0% AUC: 1.000
0001326190-26-000037

EX-99.1

2 alt-20260513xex99d1.htm

EX-99.1

Exhibit 99.1

Altimmune Announces First Quarter 2026 Financial Results and Business Update

​

Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026

$535 million in cash, cash equivalents and short-term investments as of April 30, 2026

Webcast to be held today at 8:30 a.m. ET

​

GAITHERSBURG, MD – May 13, 2026 – Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update.

“We continue to make significant progress across multiple fronts, as we enter a new phase for Altimmune,” said Jerry Durso, President and Chief Executive Officer of Altimmune. “As a result of the recent successful financing with top-tier biotech investors, we now have a strong cash position that enables us to focus on execution and delivering on our goal of bringing pemvidutide to patients with serious liver diseases and create long-term value for our shareholders. Looking ahead, we have several important milestones this year, including the initiation of the PERFORMA Phase 3 MASH trial, topline data from the RECLAIM Phase 2 AUD trial, and enrollment completion in the RESTORE Phase 2 ALD trial.”

​

Highlights and Anticipated Milestones

​

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

●Pemvidutide was granted Breakthrough Therapy Designation by the FDA based on 24-week data from the IMPACT Phase 2b trial

●The Company expects to initiate its global PERFORMA Phase 3 MASH trial in the second half of 2026, with 52-week data readout anticipated in 2029

oThe PERFORMA trial is a Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects with MASH

●The study protocol has been finalized and submitted to the FDA

●The PERFORMA Phase 3 registrational trial design is aligned with feedback from the FDA and EMA

●Scientific data to be presented at European Association for the Study of the Liver (EASL) Congress 2026

oA late-breaking oral presentation on the 48-week IMPACT data in MASH will be delivered by Dr. Mazen Noureddin, Professor of Medicine, Houston Methodist Hospital; Chief Scientific Officer and Co-Chairman, Summit Clinical Research, on May 28, 2026 at 5 p.m. CEST. Abstract selected as “Best of EASL 2026”.

oA late-breaking poster abstract: Pemvidutide Treatment Led to Fibrosis Regression After 24 Weeks in Patients with MASH: Quantitative Digital Pathology Analysis from the Phase 2b IMPACT Trial

oA poster abstract: Concurrent Responses in Multiple Non-Invasive Tests for Hepatic Inflammation and Fibrosis Following Pemvidutide Treatment: 24-Week Responder Analyses from the Phase 2b IMPACT Trial in MASH

oA poster abstract: Effect of Pemvidutide on Cardiovascular Risk Factors in Patients with MASH: 48-Week Results from the Phase 2b IMPACT Trial

​

Alcohol Use Disorder (AUD)

●Topline data from the RECLAIM Phase 2 trial of pemvidutide in AUD expected in third quarter 2026

oThe RECLAIM trial is evaluating the safety and efficacy of pemvidutide versus placebo in approximately 100 patients with AUD over a 24-week treatment period

oEnrollment was completed in November 2025, several months ahead of schedule, signaling significant interest from patients and providers in potential new AUD therapies

​

Alcohol-associated Liver Disease (ALD)

●RESTORE Phase 2 trial of pemvidutide in ALD continuing to enroll

oThe RESTORE trial is a 48-week study evaluating the safety and efficacy of pemvidutide versus placebo in approximately 100 patients with ALD

oExpect enrollment completion in third quarter 2026

​

Corporate Update

●Strengthened balance sheet

oIn January 2026, the Company completed a registered direct offering of common stock and pre-funded warrants with Alyeska Investment Group, resulting in gross proceeds of $75.0 million

oIn the first quarter of 2026, the Company raised $8.9 million via the At-the-Market (ATM) facility

oIn April 2026, the Company completed an oversubscribed public offering of common stock, pre-funded warrants, and stock warrants, resulting in gross proceeds of $225.0 million

​

​

​

​

Financial Results for the Three Months Ended March 31, 2026

●Altimmune reported cash, cash equivalents and short-term investments totaling $332 million as of March 31, 2026

oAs of April 30, 2026, the Company had approximately $535 million of cash, cash equivalents and short-term investments reflecting the net proceeds from the $225 million oversubscribed public offering of common stock, pre-funded warrants, and stock warrants in April 2026

●Research and development (R&D) expenses were $16.2 million for the three months ended March 31, 2026, compared to $15.8 million in the same period in 2025, with the increase driven primarily by the ongoing AUD and ALD trials as

About Altimmune Inc. (ALT) Earnings

This page provides Altimmune Inc. (ALT) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on ALT's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: